Supplementary Data — Leritrelvir for COVID-19: real-time meta analysis of 2 studies

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) 35% 0.65 [0.43-0.97] recov. time 20 (n) 20 (n) Improvement, RR [CI] Treatment Control Wang (DB RCT) 21% 0.79 [0.67-0.95] viral load 20 (n) 20 (n) Wang (DB RCT) 11% 0.89 [0.74-1.07] viral load 20 (n) 20 (n) Wang (DB RCT) 52% 0.48 [0.22-1.00] viral+ 20 (n) 20 (n) Wang (DB RCT) 80% 0.20 [0.09-0.45] viral+ 20 (n) 20 (n) Zhan (DB RCT) 17% 0.83 [0.74-0.93] no recov. 680 (n) 679 (n) Zhan (DB RCT) 14% 0.86 [0.77-0.97] no recov. 680 (n) 679 (n) Zhan (DB RCT) 21% 0.79 [0.63-0.98] no recov. 111/680 141/679 Zhan (DB RCT) 22% 0.78 [0.60-1.01] no recov. 89/680 114/679 Zhan (DB RCT) 16% 0.84 [0.73-0.96] viral+ 231/680 275/679 Leritrelvir COVID-19 outcomes c19early.org November 2025 Favors leritrelvir Favors control
Fig. S1. All outcomes.